Pharsight

1. Axumin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11980674	BLUE EARTH	Imaging of metastatic or recurrent cancer	Apr, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION

Strength	Dosage	Availability
9-221mCi/ML	SOLUTION	Prescription

AXUMIN family patents

2. Ayvakit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12060354	BLUEPRINT MEDICINES	Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making	Mar, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-863)	Jun 16, 2024
New Indication(I-864)	Jun 16, 2024
New Chemical Entity Exclusivity(NCE)	Jan 09, 2025
New Indication(I-912)	May 22, 2026
Orphan Drug Exclusivity(ODE-366)	Jan 09, 2027
Orphan Drug Exclusivity(ODE-356)	Jun 16, 2028
Orphan Drug Exclusivity(ODE-434)	May 22, 2030

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation

Dosage: TABLET

Strength	Dosage	Availability
300MG	TABLET	Prescription
100MG	TABLET	Prescription
200MG	TABLET	Prescription

AYVAKIT family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bortezomib patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752164	MAIA PHARMS INC	Bortezomib compositions	Sep, 2042 (17 years from now)
US12005069	MAIA PHARMS INC	Bortezomib compositions	Sep, 2042 (17 years from now)
US11679119	MAIA PHARMS INC	Bortezomib compositions	Sep, 2042 (17 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Treatment of adult patients with multiple myeloma

Dosage: SOLUTION

Strength	Dosage	Availability
3.5MG/1.4ML (2.5MG/ML)	SOLUTION	Discontinued
3.5MG/3.5ML (1MG/ML)	SOLUTION	Discontinued

BORTEZOMIB family patents

4. Daybue patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11827600	ACADIA PHARMS INC	Crystalline forms of trofinetide	Jul, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 10, 2028
Orphan Drug Exclusivity(ODE-425)	Mar 10, 2030

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 11 March, 2027

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION

Strength	Dosage	Availability
200MG/ML	SOLUTION	Prescription

DAYBUE family patents

5. Defencath patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11738120	CORMEDIX	Synthesis of taurolidine, purity profiles and polymorphs	Apr, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 15, 2028
Generating Antibiotic Incentives Now(GAIN)	Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 15 November, 2032

Market Authorisation Date: 15 November, 2023

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML)	SOLUTION	Prescription
5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML)	SOLUTION	Prescription

DEFENCATH family patents

6. Exparel patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11931459	PACIRA PHARMS INC	Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions	Mar, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 28, 2014
New Indication(I-771)	Apr 06, 2021
New Patient Population(NPP)	Mar 22, 2024
New Indication(I-929)	Nov 09, 2026

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: A method of treating pain by administering bupivacaine via local infiltration in pediatric patients aged 6 to less than 17 years old undergoing spine surgery

Dosage: INJECTABLE, LIPOSOMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
133 mg/10 mL	28 Dec, 2021	1
266 mg/20 mL	20 Aug, 2021	1		22 Jan, 2041

Strength	Dosage	Availability
266MG/20ML (13.3MG/ML)	INJECTABLE, LIPOSOMAL	Prescription
133MG/10ML (13.3MG/ML)	INJECTABLE, LIPOSOMAL	Prescription

EXPAREL family patents

7. Galafold patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833164	AMICUS THERAP US	Methods of treating Fabry disease in patients having a mutation in the GLA gene	Jan, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 10, 2023
Orphan Drug Exclusivity(ODE-205)	Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
123 mg	10 Aug, 2022	3		06 Feb, 2039

Strength	Dosage	Availability
EQ 123MG BASE	CAPSULE	Prescription

GALAFOLD family patents

8. Lumryz patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583510	AVADEL CNS	Methods of administering gamma hydroxybutyrate formulations after a high-fat meal	Feb, 2042 (17 years from now)
US11779557	AVADEL CNS	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics	Mar, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 01, 2026
Orphan Drug Exclusivity(ODE-431)	May 01, 2030
Orphan Drug Exclusivity(ODE-494)	Oct 16, 2031

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation; Treatment of cataplexy or excessive daytime sleepiness in patients with narco...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

Strength	Dosage	Availability
6GM/PACKET	FOR SUSPENSION, EXTENDED RELEASE	Prescription
4.5GM/PACKET	FOR SUSPENSION, EXTENDED RELEASE	Prescription
7.5GM/PACKET	FOR SUSPENSION, EXTENDED RELEASE	Prescription
9GM/PACKET	FOR SUSPENSION, EXTENDED RELEASE	Prescription

LUMRYZ family patents

9. Ogsiveo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11612588	SPRINGWORKS	Chlorinated tetralin compounds and pharmaceutical compositions	Jul, 2042 (17 years from now)
US11504354	SPRINGWORKS	Chlorinated tetralin compounds and pharmaceutical compositions	Jul, 2042 (17 years from now)
US11807611	SPRINGWORKS	Chlorinated tetralin compounds and pharmaceutical compositions	Sep, 2042 (17 years from now)
US11844780	SPRINGWORKS	Chlorinated tetralin compounds and pharmaceutical compositions	Sep, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 27, 2028
ODE(ODE)	Nov 27, 2030
Orphan Drug Exclusivity(ODE-452)	Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET

Strength	Dosage	Availability
EQ 50MG BASE	TABLET	Prescription
EQ 150MG BASE	TABLET	Prescription
EQ 100MG BASE	TABLET	Prescription

OGSIVEO family patents

10. Ponvory patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951097	VANDA PHARMS INC	Methods of treating multiple sclerosis	Oct, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults being treated with a ...

Dosage: TABLET

Strength	Dosage	Availability
20MG	TABLET	Prescription
10MG	TABLET	Prescription
9MG	TABLET	Prescription
8MG	TABLET	Prescription
7MG	TABLET	Prescription
6MG	TABLET	Prescription
5MG	TABLET	Prescription
4MG	TABLET	Prescription
3MG	TABLET	Prescription
2MG	TABLET	Prescription

PONVORY family patents

11. Qinlock patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11779572	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Oct, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 15, 2025
Orphan Drug Exclusivity(ODE-298)	May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumors in patients having pre-existing severe hepatic impairment and suffering from an adverse event while being administered ripretinib daily

Dosage: TABLET

Strength	Dosage	Availability
50MG	TABLET	Prescription

QINLOCK family patents

12. Sezaby patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857683	SUN PHARM INDS INC	Stabilization of phenobarbital sodium for injection	Apr, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-414)	Nov 17, 2029

Drugs and Companies using PHENOBARBITAL SODIUM ingredient

Market Authorisation Date: 17 November, 2022

Treatment: Method of treating neonatal seizures

Dosage: POWDER

Strength	Dosage	Availability
100MG/VIAL	POWDER	Prescription

SEZABY family patents

13. Sunosi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771666	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US11771667	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US11793776	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US12090126	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US12064411	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US11872204	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US12005036	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US11872203	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US12036194	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)
US11779554	AXSOME MALTA	Methods of administering solriamfetol to lactating women	Dec, 2042 (18 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 17, 2024
Orphan Drug Exclusivity(ODE-254)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness in a breast-feeding patient while reducing infant exposure to solriamfetol

Dosage: TABLET

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg and 150 mg	20 Jun, 2023	6		19 Mar, 2040

Strength	Dosage	Availability
EQ 150MG BASE	TABLET	Prescription
EQ 75MG BASE	TABLET	Prescription

SUNOSI family patents

14. Talicia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11878011	REDHILL	Method for eradicating Helicobacter pylori infection in patients regardless of body mass index	May, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 01, 2022
Generating Antibiotic Incentives Now(GAIN)	Nov 01, 2027

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Treatment of helicobacter pylori infection using the administered dosage forms in adults with different body mass index determinations

Dosage: CAPSULE, DELAYED RELEASE

Strength	Dosage	Availability
250MG;EQ 10MG BASE;12.5MG	CAPSULE, DELAYED RELEASE	Prescription

TALICIA family patents

15. Tezruly patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224572	NOVITIUM PHARMA	Stable oral liquid composition of terazosin	Jan, 2042 (17 years from now)

Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 July, 2024

Treatment: Treatment of symptomatic benign prostatic hyperplasia (bph) in patients who are in need of a liquid composition of terazosin

Dosage: SOLUTION

Strength	Dosage	Availability
EQ 1MG BASE/ML	SOLUTION	Discontinued

TEZRULY family patents

16. Tyvaso patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826327	UNITED THERAP	Treatment for interstitial lung disease	Feb, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jul 30, 2012
Orphan Drug Exclusivity(ODE)	Jul 30, 2016
M(M-145)	May 20, 2017
New Indication(I-856)	Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.6 mg/mL, 2.9 mL ampules	13 Apr, 2015	1		15 Dec, 2028	Extinguished

Strength	Dosage	Availability
0.6MG/ML	SOLUTION	Prescription

TYVASO family patents

17. Tyvaso Dpi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826327	UNITED THERAP	Treatment for interstitial lung disease	Feb, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 23, 2025

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER

TYVASO DPI family patents

18. Vevye patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12059449	HARROW EYE	Ophthalmic composition for treatment of dry eye disease	Apr, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION

VEVYE family patents

19. Vivimusta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844784	AZURITY	Stable pharmaceutical compositions of bendamustine	Jul, 2042 (17 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2022

Treatment: NA

Dosage: SOLUTION

VIVIMUSTA family patents

20. Xelstrym patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559501	NOVEN PHARMS INC	Transdermal amphetamine compositions with low levels of carbamate	Jan, 2042 (17 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: NA

Dosage: SYSTEM

XELSTRYM family patents

21. Zunveyl patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11795176	ALPHA COGNITION	Solid forms of Alpha-1062 gluconate	Jan, 2042 (17 years from now)

Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient

Market Authorisation Date: 26 July, 2024

Treatment: Treatment of mild to moderate dementia of the alzheimer's type

Dosage: TABLET, DELAYED RELEASE

Strength	Dosage	Availability
0.032MG/INH	POWDER	Prescription
0.064MG/INH	POWDER	Prescription
0.016MG/INH	POWDER	Prescription
0.048MG/INH	POWDER	Prescription

Strength	Dosage	Availability
9MG/9HR	SYSTEM	Prescription
13.5MG/9HR	SYSTEM	Prescription
18MG/9HR	SYSTEM	Prescription
4.5MG/9HR	SYSTEM	Prescription

Strength	Dosage	Availability
EQ 5MG BASE	TABLET, DELAYED RELEASE	Prescription
EQ 10MG BASE	TABLET, DELAYED RELEASE	Prescription
EQ 15MG BASE	TABLET, DELAYED RELEASE	Prescription

Pharsight

Pharsight

Drug Patents Expiring in 2042

1. Axumin patent expiration

AXUMIN family patents

2. Ayvakit patent expiration

AYVAKIT family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Bortezomib patent expiration

BORTEZOMIB family patents

4. Daybue patent expiration

DAYBUE family patents

5. Defencath patent expiration

DEFENCATH family patents

6. Exparel patent expiration

EXPAREL family patents

7. Galafold patent expiration

GALAFOLD family patents

8. Lumryz patent expiration

LUMRYZ family patents

9. Ogsiveo patent expiration

OGSIVEO family patents

10. Ponvory patent expiration

PONVORY family patents

11. Qinlock patent expiration

QINLOCK family patents

12. Sezaby patent expiration

SEZABY family patents

13. Sunosi patent expiration

SUNOSI family patents

14. Talicia patent expiration

TALICIA family patents

15. Tezruly patent expiration

TEZRULY family patents

16. Tyvaso patent expiration

TYVASO family patents

17. Tyvaso Dpi patent expiration

TYVASO DPI family patents

18. Vevye patent expiration

VEVYE family patents

19. Vivimusta patent expiration

VIVIMUSTA family patents

20. Xelstrym patent expiration

XELSTRYM family patents

21. Zunveyl patent expiration

ZUNVEYL family patents

Related content

Have Questions?

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bortezomib patent expiration